WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004005340) FUSION POLYPEPTIDE COMPRISING EPIDERMAL GROWTH FACTOR AND HUMAN SERUM ALBUMIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/005340    International Application No.:    PCT/KR2003/001309
Publication Date: 15.01.2004 International Filing Date: 02.07.2003
Chapter 2 Demand Filed:    03.02.2004    
IPC:
A61K 38/00 (2006.01), C07K 14/485 (2006.01), C07K 14/765 (2006.01), C12N 15/62 (2006.01), C12N 15/82 (2006.01)
Applicants: NEXGEN BIOTECHNOLOGIES, INC. [KR/KR]; 2Fl. Yurim Bldg., 65-1, Wonchon-dong, Yusung-gu, Daejon Metropolitan City 305-370 (KR) (For All Designated States Except US).
LEE, Sun [KR/KR]; (KR) (For US Only).
YOO, Jae-Geun [KR/KR]; (KR) (For US Only).
PARK, Sun-Hee [KR/KR]; (KR) (For US Only)
Inventors: LEE, Sun; (KR).
YOO, Jae-Geun; (KR).
PARK, Sun-Hee; (KR)
Agent: SESHIN PATENT & LAW FIRM; 8th Fl., KFSB Bldg., 16-2, Yeoedo-dong, Yeongdeungpo-gu, Seoul 150-010 (KR)
Priority Data:
10-2002-0038165 03.07.2002 KR
Title (EN) FUSION POLYPEPTIDE COMPRISING EPIDERMAL GROWTH FACTOR AND HUMAN SERUM ALBUMIN
(FR) POLYPEPTIDE DE FUSION COMPRENANT LE FACTEUR DE CROISSANCE EPIDERMIQUE ET DE L'ALBUMINE SERIQUE HUMAINE
Abstract: front page image
(EN)The present invention relates to a fusion polypeptide comprising epidermal growth factor (EGF) and human serum albumin linked to the C-terminal or N-terminal of EGF; and in which the stability of EGF is enhanced by virtue of human serum albumin, a nucleotide sequence encoding the fusion polypeptide, and a cosmetic and/or pharmaceutical composition comprising the fusion polypeptide.
(FR)La présente invention concerne un polypeptide de fusion comprenant le facteur de croissance épidermique (EGF) et de l'albumine sérique humaine liée à l'extrémité C-terminale ou N-terminale de l'EGF. Dans la présente invention, la stabilité de l'EGF est accrue par l'albumine sérique humaine. L'invention concerne également une séquence nucléotidique codant pour le polypeptide de fusion et une composition cosmétique et/ou pharmaceutique comprenant le polypeptide de fusion.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)